The Very Good Food Company | Management’s Discussion and Analysis
equipment of $122,459, loss on termination of lease of $151,491, loss on disposal of equipment of $1,490 and depreciation of $1,601,139. The decrease in working capital was largely due to a decrease in accounts receivable of $1,104,631 and prepaid and deposits of $2,645,433, which was offset by an increase in inventory of $1,865,955 and a decrease in accounts payable and accrued liabilities of $2,686,481. During the six months ended June 30, 2021, net cash used in operating activities was $14,052,481 as a result of the net loss for the period of $27,529,309, partially offset by a change in non-cash expenses related to share-based compensation of $14,609,998, finance expense of $764,182, depreciation of $841,652 and shares and units issued for services of $227,471.
Investing activities
Net cash used in investing activities for the six months ended June 30, 2022, was $2,623,186 primarily attributed to $2,641,780 of capital expenditures and leasehold improvements incurred for the Rupert Facility and Patterson Facility in Q1, acquisition of right-of-use assets of $36,074 for equipment leased and $412,608 of security deposits paid for equipment purchases for Rupert Facility and Patterson Facility, and the payment of $598,000 of contingent consideration in relation to the acquisitions that took place in fiscal year 2021, offset by a refund of security deposits of $655,008, and repayment of $410,268 received from a loan to a related party. Net cash used in investing activities for the six months ended June 30, 2021 was $8,281,414 primarily attributed to capital expenditures and leasehold improvements incurred for the commissioning of the Rupert Facility. In addition, the Company paid $1,250,000 for the acquisition of The Cultured Nut Inc. and Lloyd-James Marketing Group Inc.
Financing activities
Net cash provided by financing activities for the six months ended June 30, 2022, was $4,692,870 mainly due to $182,456 received from the exercise of stock options, $8,184,762 received from the issuance of common shares, common share equivalents and warrants, and $32,288 of advances received from the Credit Facility partially offset by payments of lease liabilities of $1,364,642, repayment of loans payable and other liabilities of $994,302, interest payment of $242,356, and $168,677 paid for the settlement of the lease for the formerly planned Mount Pleasant Flagship Store location. The Company also incurred $936,659 of share issuance costs in relation to the private placement that closed in June 2022. Net cash used in financing activities for the six months ended June 30, 2021, was $3,172,787 due to $2,262,957 received from proceeds from the exercise of warrants and stock options, $28,999 proceeds from subscription received, and proceeds from loans payable $1,891,092; this was partially offset by payment of lease liabilities of $532,097, repayment of loans payable $240,000, and payment of deferred financing costs of $238,164.
During the six months ended June 30, 2022, the Company received a total of $32,288 pursuant to the Credit Facility. During the six months ended June 30, 2022, the Company recognized interest and accretion expense on the Credit Facility fee payable of $83,183 and interest expense of $229,599 related to the Revolving Line of Credit and Term Loan. The Company also incurred an unused line of credit fee of $12,259. As at June 30, 2022, $38,654 is outstanding for interest and $2,017 is outstanding for unused line of credit fees, which are included in accounts payable and accrued liabilities. On June 8, 2022, the loan agreement for the Credit Facility was amended to modify the Credit Facility fee payment schedule. As a result, the Company recognized a gain of $16,783 on debt modification.
The Company incurred debt financing costs totalling $5,303,563, which will be amortized over the term of the Credit Facility at the effective interest rate. During the six months ended June 30, 2022, the Company recognized accretion expense of the deferred financing costs of $1,491,480. As at June 30, 2022, the remaining carrying value of the deferred financing costs was $2,433,263.
Prospectus Offerings and Registration Statement Use of Proceeds
On October 5, 2021, the Company filed a Form F-10 registration statement (File No. 333-260064) (the “F- 10 Registration Statement”) which was made effective by the SEC on October 8, 2021 and registered $100,000,000 (US$79,026,394.80) of an indeterminate amount of common shares, warrants, debt securities, subscriptions receipts and units. Pursuant to this F-10 Registration Statement, on October 19, 2021, the Company closed a registered direct offering (the “October 2021 Offering”) with certain U.S. institutional investors for the purchase and sale of an aggregate of 15,000,000 units of the Company consisting of one Common Share and one half of one Common Share purchase warrant (each, an “October 2021 Unit”) at a price of US$2.00 per October 2021 Unit for gross proceeds of $37,078,200 (US$30,000,000). The October 2021 Offering was fully subscribed and the lead placement agents were A.G.P./Alliance Global Capital and Roth Capital Partners, with placement agent fees totaling $2.2 million (US$1.8 million). In addition, there were estimated expenses for the October 2021 Offering totaled $617,970 (US$500,000), consisting of regulatory filing fees, transfer agent costs, professional advisory fees, auditor review, and legal fees and expenses. The net proceeds from the October 2021 offering after deducting these expenses was $34,335,242 (US$27.7 million). The 15,000,000 October 2021 Units sold in this transaction remain the only securities sold in connection with the F-10 Registration Statement. The following table provides an update on the anticipated use of proceeds raised in the October 2021 Offering, along with amounts expended. None of the payments listed in the table below constitute direct or indirect payments to directors, officers, general partners of the issuer or their associates; to persons owning 10% or more of any class of the issuer’s equity securities; and
17